Equitable Access to High-Cost Pharmaceuticals (ePub)
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.
- Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs
- Incorporates existing guidelines and recommendations by international organizations
- Compares and contrasts how different countries fund and police high-cost drug access
- Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing
- Reviews novel pharmaceuticals of current research interest
He is globally recognized for his research in pharmaceutical policy and practice, including the quality use of medicines, clinical pharmacy practice, access to medicines and issues related to pharmacoeconomics. Previously he was the Head of Pharmacy Practice at School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a Ph.D. in pharmacy practice, Dr. Babar is the recipient of prestigious “Research Excellence Award from the University of Auckland.
He has active research collaborations and linkages in over 30 countries including in World’s leading Universities such as Boston University School of Public Health, Harvard Medical School, Austrian Health Institute, University of Auckland, Monash University and at the University of Sydney. He has published over 150 papers, book chapters, conference papers including in high impact journals such as PLoS Medicine and in Lancet Oncology. Dr. Babar has acted as an advisor for World Health Organization, Health Action International, the International Union Against Tuberculosis and Lung Disease, World Bank, International Pharmaceutical Federation (FIP) and for the Pharmaceutical Management Agency of New Zealand.
His recent work includes a number of high-quality books including "Economic evaluation of pharmacy services", Pharmaceutical prices in 21st century, “ Pharmacy Practice Research Methods and “Pharmaceutical policies in countries with developing healthcare systems. Published by Elsevier and Adis/Springer, the work is used in curriculum design, policy development and for referral all around the globe.
He is the Editor in Chief of Encyclopedia of Pharmacy Practice and Clinical Pharmacy, which is due to be published by Elsevier in early 2019.The Encyclopedia is comprehensive in nature and it aims to cover multiple
Professor Babar is also the Editor-in-Chief of BMC Journal of Pharmaceutical Policy and Practice and can be contacted at z.babar@hud.ac.uk
- Autor: Zaheer-Ud-Din Babar
- 2018, 238 Seiten, Englisch
- Herausgegeben: Zaheer-Ud-Din Babar
- Verlag: Elsevier Science & Techn.
- ISBN-10: 0128119624
- ISBN-13: 9780128119624
- Erscheinungsdatum: 27.02.2018
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
- Dateiformat: ePub
- Größe: 4.68 MB
- Mit Kopierschutz
- Vorlesefunktion
Schreiben Sie einen Kommentar zu "Equitable Access to High-Cost Pharmaceuticals".
Kommentar verfassen